Delivery Order SPE2DB22D2007-SPE2DB25FJ3XM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Actemra 162 mg/0.9 mL syringes, with a ceiling value of $23,369.56 and a firm fixed price structure. The delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. Performance is scheduled for...
- The Defense Logistics Agency awarded a delivery order valued at $3,328.29 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This firm fixed-price delivery order is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,633.52 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and is set to be completed by August 1, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving as the place of performance for this federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $32,313.93 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed-price contract, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a contract ceiling value of $12,196.90. This firm fixed-price delivery order, issued on August 1, 2025, carries an ultimate completion date of August 4, 2025, and represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 12, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $4,594.53. This firm fixed-price, competitively awarded delivery order is funded by the Defense Logistics Agency's Medical Supply Chain, a defense-focused federal agency, and has an ultimate completion date of August 13, 2025. The award was made under no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $11,196.02 to AmerisourceBergen Drug Corp for 4,568,895,450 units of Actemra 400 mg/20 mL vials on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract utilizes firm fixed pricing with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency (DLA) awarded a $7,362.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 162 mg/0.9 mL Actemra syringes on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor, fulfilled this delivery order under its...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3XMDelivery Order
The Defense Logistics Agency awarded a $3,779.36 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-set-aside, firm fixed price contract is scheduled for completion by August 14, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child delivery order under a larger Indefinite Delivery Contract vehicle. This delivery order represents a continuation of AmerisourceBergen Drug Corp's extensive relationship with DLA's Medical Supply Chain. The contractor holds a significant IDC with DLA Troop Support Medical valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling supply of medications, vaccines, and medical supplies to military healthcare programs worldwide. The Actemra delivery is consistent with the contractor's portfolio of specialty pharmaceutical products supporting federal medical procurement needs across the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 8/13/25 |